 The principal outcome is the hearing loss defined by the difference between the average permanent threshold shift PTS in dB decibel at four pure tone high frequencies 9, 10, 12.5 and 14 kHz using the data from the audiograms done before and after Cisplatin therapy, for each patient and for each ear. The average PTS in dB at these pure tone high frequencies will be compared between the treated and the control ears using a t-test for paired data. A planned interim analysis will be conducted when half of the anticipated participants would have completed the follow-up. In the interim analysis, the test for superiority will be done with two-sided alpha0.01 and the results shown only to the Data and Safety Monitoring Committee DSMC. If the DSMC recommendation is to continue the trial as planned, the final analysis will be done with two-sided alpha0.045 in order to keep the trial overall statistical significance level to 0.05. 